Commentary|Videos|January 23, 2025
5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial
Author(s)Javier Pinilla, MD, PhD, Talha Badar, MBBS, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.
Advertisement
Episodes in this series
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
A rituximab biosimilar has been approved by the FDA.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
4
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
5